A DPP-IV and ACE dual inhibitory peptide LP-6 derived from Lentinus edodes stalk protein and its application

By extracting and preparing the dual inhibitory peptide LP-6 of DPP-IV and ACE from the stem of shiitake mushrooms, the problems of side effects and single inhibitory activity in the existing technology have been solved, and a highly efficient dual inhibitory effect has been achieved. This method is suitable for preparing health products with hypoglycemic and hypotensive functions.

CN118496318BActive Publication Date: 2024-11-15SOUTH CHINA UNIV OF TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410961358.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-15
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

Existing chemically synthesized DPP-IV/ACE inhibitors have side effects, and most studies only target single inhibitory activity, lacking effective dual inhibitory peptides of DPP-IV and ACE, thus failing to effectively prevent and treat diabetes mellitus with hypertension.

Method used

The DPP-IV and ACE dual inhibitory peptide LP-6 was extracted from the stem of shiitake mushroom and prepared by chemical synthesis or enzymatic hydrolysis. Highly active peptides were screened by ultrafiltration, ion column and gel column chromatography, and LDHGFP peptide was screened by molecular docking technology.

Benefits of technology

LP-6 exhibited highly efficient DPP-IV and ACE inhibition rates of 74.3±2.23% and 75.18±2.26%, respectively, with IC50 values ​​of 0.3221mM and 0.2521mM, demonstrating significant dual inhibitory activity. Furthermore, it showed no significant toxicity to Caco-2 cells, providing a novel raw material for health supplements for the prevention and treatment of type II diabetes mellitus with hypertension.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118496318B_ABST
    Figure CN118496318B_ABST
Patent Text Reader

Abstract

The present invention discloses a shiitake mushroom stalk protein-derived DPP-IV and ACE dual inhibitory peptide LP-6 and its application. The present invention screened out a new polypeptide LP-6 from shiitake mushroom stalks that can significantly inhibit the enzyme activity of DPP-IV and ACE at the same time, and its sequence has not been reported before at home and abroad. The inhibition rates of LP-6 (1.0 mg / mL) on DPP-IV and ACE were 74.3±2.23% and 75.18±2.26%, respectively, and the IC50 values ​​were 0.3221 mM and 0.2521 mM, respectively, which are more active than most existing inhibitory peptides, and provide new raw materials for the development of health products or functional foods for the prevention and treatment of type 2 diabetes with hypertension.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of bioactive peptides, and in particular to a Lentinus edodes stipe protein-derived DPP-IV and ACE dual inhibitory peptide LP-6 and applications thereof. Background Art

[0002] Diabetes is a chronic disease caused by insulin secretion defects or insulin action disorders. Type 2 diabetes is characterized by increased insulin resistance and insufficient insulin secretion due to β-cell dysfunction, which can lead to many macrovascular and microvascular complications, affect multiple organs, and seriously threaten human health. Dipeptidyl peptidase IV (DPP IV) is a cell surface serine protease that can degrade glucose-dependent insulinotropic peptide (GIP) and glucagon like peptide-1 (GLP-1), thereby reducing insulin secretion and increasing blood sugar. Therefore, DPP-IV is regarded as an important target for the treatment of diabetes.

[0003] Hypertension is a high-risk factor for the most common health problems such as headaches, fatigue or restlessness, arrhythmias, palpitations and tinnitus, as well as stroke, cardiovascular disease (CHD), renal insufficiency, disability and death. The control of hypertension is related to multiple metabolic pathways, among which angiotensin converting enzyme is a key regulatory factor. Angiotensin converting enzyme (ACE) is a zinc-dependent carboxypeptidase that can cause hypertension by disrupting the balance of the renin angiotensin system (RAS) and the kallikrein kinin system (KKS). Specifically, ACE catalyzes the conversion of inactive angiotensin I (Ang-I) into active angiotensin II (Ang-Ⅱ), which then acts on receptors to contract arteriolar smooth muscle. On the other hand, bradykinin, which has a vasodilating effect, will be degraded by ACE into inactive fragments, causing blood pressure to rise. Therefore, the regulation of ACE is regarded as an important target for the treatment of hypertension.

[0004] At present, diabetes and hypertension are becoming younger and more common. The probability of diabetes patients suffering from hypertension is about twice that of non-diabetic people. This is because there is a certain correlation between the pathogenesis of the two. The increase in blood viscosity and fat density in diabetic patients will cause damage to the vascular endothelium, trigger a series of lesions, and lead to hypertension. Hypertension can lead to abnormal glucose metabolism, resulting in poor blood sugar control in diabetic patients. Although there are currently a variety of chemically synthesized DPP-IV / ACE inhibitors widely used in clinical treatment, they can cause a variety of side effects. Although there have been many studies on food-borne DPP-IV / ACE inhibitory peptides, most of them are only aimed at single inhibitory activity. Therefore, the study of DPP-IV and ACE dual inhibitory peptides is conducive to the simultaneous regulation of DPP-IV and ACE, and the prevention and treatment of diabetes with hypertension.

[0005] Shiitake (English name: Shiitake, scientific name: Lentinus edodes ), also known as mushrooms, is the second largest edible fungus in the world. Shiitake mushrooms are rich in essential amino acids, nucleotides, vitamins and other nutrients, as well as polysaccharides, dietary fiber, ergosterol and shiitake purine and other active substances, which have the effects of enhancing immunity, anti-oxidation, preventing diabetes, preventing cancer and preventing cardiovascular and cerebrovascular diseases. At present, shiitake protein has become a waste left after the production of shiitake polysaccharides, and shiitake stems are discarded in large quantities due to their poor taste or are only used for feed processing. Therefore, using shiitake stems as raw materials to prepare DPP-Ⅳ and ACE dual inhibitory peptides is beneficial to the utilization of shiitake resources. Summary of the invention

[0006] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide a DPP-IV and ACE dual inhibitory peptide LP-6 derived from Lentinus edodes stipe protein.

[0007] Another object of the present invention is to provide the application of the above-mentioned Lentinus edodes stipe protein source DPP-IV and ACE dual inhibitory peptide LP-6.

[0008] The purpose of the present invention is achieved through the following technical solutions:

[0009] A DPP-IV and ACE dual inhibitory peptide derived from Lentinus edodes stalk protein, characterized by comprising at least one of the following polypeptides:

[0010] LP-6, whose amino acid sequence is LDHGFP.

[0011] The shiitake mushroom stalk protein-derived DPP-IV and ACE dual inhibitory peptide is prepared by chemical synthesis or biological enzymatic hydrolysis.

[0012] Application of the above-mentioned Lentinus edodes stalk protein-derived DPP-IV and ACE dual inhibitory peptide in the preparation of DPP-IV and / or ACE inhibitors.

[0013] Application of the above-mentioned Lentinus edodes stalk protein-derived DPP-IV and ACE dual inhibitory peptide in the preparation of DPP-IV / ACE dual inhibitors.

[0014] Application of the above-mentioned Lentinus edodes stalk protein-derived DPP-IV and ACE dual inhibitory peptide in the preparation of drugs for lowering blood sugar and / or treating cardiovascular diseases.

[0015] The application of the above-mentioned Lentinus edodes stalk protein-derived DPP-IV and ACE dual inhibitory peptide in the preparation of a drug capable of simultaneously lowering blood sugar and treating cardiovascular diseases.

[0016] The use of the above-mentioned Lentinus edodes stipe protein-derived DPP-IV and ACE dual inhibitory peptide in the preparation of a health product with auxiliary blood sugar lowering function and / or auxiliary blood pressure lowering function.

[0017] The application of the above-mentioned Lentinus edodes stalk protein-derived DPP-IV and ACE dual inhibitory peptide in the preparation of a health product having both the auxiliary blood sugar lowering function and the auxiliary blood pressure lowering function.

[0018] Compared with the prior art, the present invention has the following advantages and effects:

[0019] (1) The present invention screened out a new polypeptide LP-6 from Lentinus edodes stems that has the ability to simultaneously inhibit the activity of DPP-IV and ACE enzymes. The sequence of LP-6 has not been reported before at home or abroad.

[0020] (2) The inhibition rates of LP-6 on DPP-Ⅳ and ACE were 74.3±2.23% and 75.18±2.26%, respectively, and the IC50 values ​​were 0.3221mM and 0.2521mM, respectively. These are more active than most existing inhibitory peptides and provide a new raw material for the development of health products or functional foods for the prevention and treatment of type 2 diabetes with hypertension.

[0021] (3) The present invention uses traditional methods such as ultrafiltration, ion column and gel column chromatography combined with molecular docking technology to screen peptides with high dual inhibitory activity against DPP-IV and ACE and high biosafety, thereby excluding peptides with low activity and low binding energy from a large number of peptides, thereby reducing the workload of manual verification. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is the elution curve of the anion exchange chromatography column in Example 1 of the present invention.

[0023] Figure 2 The DPP-IV and ACE inhibition rates of the four main components collected by elution from the anion exchange chromatography column and the mixed components in the enzymatic hydrolyzate in Example 1 of the present invention are shown.

[0024] Figure 3 This is the elution curve of the gel chromatography column in Example 1 of the present invention.

[0025] Figure 4 The DPP-IV and ACE inhibition rates of the two main components collected by elution from the gel chromatography column and the mixed components in the enzymatic hydrolyzate in Example 1 of the present invention.

[0026] Figure 5 Schematic diagram of the molecular docking sites of the crystal structures of peptide LP-6 with DPP-IV and ACE.

[0027] Figure 6 To screen the DPP-Ⅳ and ACE inhibition rates of the four peptides obtained.

[0028] Figure 7 is the IC50 value of peptide LP-6.

[0029] Figure 8 The changes in cell viability after Caco-2 cells were co-cultured with peptide LP-6 (0.5mM / 1.0mM / 2.0mM) for 24h. DETAILED DESCRIPTION

[0030] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0031] If the specific experimental conditions are not specified in the following embodiments, the conventional experimental conditions or the experimental conditions recommended by the reagent company are usually followed. The materials and reagents used, unless otherwise specified, are all reagents and materials obtained from commercial sources.

[0032] Example 1 Preparation of mixed polypeptides from enzymatic hydrolysis of Lentinus edodes stems

[0033] 10 g of Lentinus edodes stem protein was added to 400 mL of distilled water (solid-liquid ratio 1:40), and after ultrasonic homogenization for 30 min, the pH was adjusted to 10.5 with NaOH solution, and subtilisin (based on protein mass) was added at a ratio of 2600 U / g. The protein was hydrolyzed on a shaker (45 ° C, 220 r / min) for 6 h, during which the pH was kept at the set value. After the enzymatic hydrolysis was completed, the pH of the solution was adjusted to 7.0, and the enzyme was inactivated in a boiling water bath for 10 min. The supernatant was collected by centrifugation, precipitated with 80% ethanol to remove the enzyme, unhydrolyzed macromolecular protein and a small amount of polysaccharide, dialyzed for desalination, and freeze-dried to obtain Lentinus edodes stem enzymatic hydrolysis mixed polypeptides.

[0034] Example 2 Isolation of DPP-IV and ACE dual inhibitory peptides

[0035] The enzymatic mixed peptides of Lentinus edodes stems were separated by ultrafiltration, DEAE-cellulose anion column chromatography, and polysaccharide gel G-15 column chromatography to screen the Lentinus edodes stem peptide components with high DPP-Ⅳ and ACE inhibitory activities. The specific experimental steps are as follows:

[0036] (1) The mixed peptide powder of Lentinus edodes protease hydrolyzate prepared in Example 1 was dissolved in distilled water to prepare a solution with a concentration of 1.0 mg / mL, and filtered through a 0.45 μm filter membrane. Subsequently, a SCM cup-type ultrafilter was used to pass the Lentinus edodes protease peptide mixture through filter membranes (10 kDa and 3 kDa) under nitrogen pressure, and the DPP-IV and ACE inhibition rates of the permeate and the concentrate were measured respectively, and the components with high inhibition rates were selected for further purification.

[0037] (2) The fraction <3 kDa with a higher inhibition rate obtained after ultrafiltration was subjected to DEAE-cellulose anion column chromatography and gradient eluted with a salt (NaCl) solution; the sample volume was 2 mL, 8 mL was collected in each tube, and the collection was stopped after the peak reached the baseline equilibrium, and the absorbance of the eluate in each tube was measured at 220 nm; reference Figure 1 As shown, four main components F1 to F4 were collected, and the inhibition rates of DPP-Ⅳ and ACE in the four components were measured. The results are shown in Figure 2 shown.

[0038] DPP-Ⅳ inhibition rate determination:

[0039] Take the dry powder of the sample to be tested and prepare it into a 1.0 mg / mL sample solution with DPP-IV detection buffer. Sitagliptin is used as the positive control. According to the settings of different groups in Table 1, the reagents are added to the 96-well plate in sequence. At 37°C, the fluorescence intensity FLU (λex=360nm / λem=460nm) of each well within 0-30min is measured in the kinetic mode. The measurement is performed every 5 minutes, and then the curves of fluorescence intensity change with time are plotted respectively, and linear fitting is performed. The DPP-IV inhibition rate is calculated according to the following formula:

[0040] DPP-Ⅳ inhibition rate / % = (Slope of EC-Slope of S) / Slope of EC × 100%;

[0041] In the formula, Slope of EC is the slope of the blank control group; Slope of S is the slope of the experimental group.

[0042] Table 1 Determination method of DPP-IV inhibitory activity

[0043]

[0044] Note: “——” in the table means adding the same volume of DPP-Ⅳ detection buffer as that of the experimental group;

[0045] ACE inhibition rate determination:

[0046] 60 μL of sample solution (1.0 mg / mL) was mixed with 10 μL of ACE enzyme solution (0.1 U / mL), incubated in a 37 ℃ water bath for 10 min, and 50 μL of substrate HHL (hippuryl-histidyl-leucine) solution was added. After the entire reaction system was incubated in a 37 ℃ water bath for 60 min, 100 μL of 1 mol / L HCl solution was added to terminate the reaction. The solution was filtered through a 0.45 μm filter membrane, and 10 μL of the sample was injected for liquid chromatography analysis. Each sample was measured in triplicate, and the data was considered qualified if the standard deviation was within 10%. The average value of the three parallel samples was taken as the result.

[0047] HPLC analysis conditions:

[0048] Chromatographic column: Agilent-C18 (4.6 mm×250 mm, 5 µm); liquid chromatography detection conditions: detection wavelength: 228 nm; mobile phase: 75% A (100% water, containing 0.1% trifluoroacetic acid), 25% B (100% acetonitrile); flow rate: 1.0 mL / min; column temperature: 28°C; injection volume: 10 µL.

[0049] Table 2 Determination of ACE inhibitory activity

[0050]

[0051] Note: “——” indicates adding the same volume of boric acid-borax buffer as that of the experimental group instead;

[0052] Calculation of ACE inhibition rate: ACE inhibition rate / % = ([HA]c-[HA]s) / ([HA]c-[HA]H) × 100;

[0053] Wherein: [HA]c is the hippuric acid concentration of the control group; [HA]s is the hippuric acid concentration of the experimental group; [HA]H is the hippuric acid concentration of the blank control.

[0054] (3) From the four main components obtained by anion column chromatography, the F1 component with the highest inhibition rate of both DPP-Ⅳ and ACE was selected for Sephadex G-15 column chromatography, and eluted with distilled water at 1.0 mL / min. 3 mL was collected in each tube. The collection was stopped when the peak reached baseline equilibrium, and the absorbance value of the eluate in each tube was measured at 220 nm. The results are shown in Figure 3 As shown, two main components F1-1 and F1-2 were collected, and the inhibition rates of DPP-Ⅳ and ACE of the two components were determined. The results are shown in Figure 4 As shown, it can be seen that the component F1-2 has a higher inhibition rate of both DPP-Ⅳ and ACE.

[0055] Example 3 Sequencing and screening of DPP-IV and ACE dual inhibitory peptides

[0056] (1) Sample purification and identification

[0057] The F1-2 component obtained after separation in Example 2 was desalted using a ZipTip C18 column, and the treated peptide was dissolved in 20 μL of dissolving solution (0.1% formic acid), centrifuged at 17000 r / min and 4°C for 20 min, the supernatant was taken, 4 μL was injected, and the polypeptide sequence was identified by liquid chromatography-tandem mass spectrometry analysis (LC-MS / MS) and de novo sequencing (de-novo).

[0058] HPLC parameters: mobile phase A: 0.1% formic acid, mobile phase B: 0.1% formic acid ACN, flow rate 0.25 mL / min. Mass spectrometry parameters: positive electrospray ionization mode, capillary energy 2.5 kV, sampling cone 30 V. The analysis was performed at normal scanning resolution with an m / z range of 50 to 1900.

[0059] Component F1-2 was identified by liquid chromatography, tandem mass spectrometry and de novo sequencing to obtain 6532 peptides, of which hexapeptides and heptapeptides were the most prominent, at 1716 and 1613, respectively. The amino acid distribution showed that the number of peptides containing hydrophobic amino acids in component F1-2 reached more than 90%, and the peptides with a hydrophobic amino acid content of 50-75% were the most abundant, accounting for 48.9% of the total number of peptides, and most of them were located at both ends of the peptides. Since the content and position of hydrophobic amino acids in DPP-Ⅳ and ACE inhibitory peptides are closely related to their activity, these peptides rich in hydrophobic amino acids significantly improved the activity of component F1-2.

[0060] (2) Screening of peptides that dually inhibit DPP-Ⅳ and ACE enzyme activity based on the database

[0061] The peptides obtained by sequencing were screened from the following six dimensions:

[0062] Confidence: From the peptide sequences identified by LC-MS / MS, peptides with a confidence level of ALC>80% (more reliable) were screened out;

[0063] Peptide content: The peak area of ​​a peptide segment can reflect its content. From peptide segments with a confidence level > 80%, select peptides with a peak area > 10e 5 peptides;

[0064] Biological activity scoring: Peptides with Area>10×e5 were predicted on the PeptideRanker website, and peptides with PeptideRanker>0.5 were screened;

[0065] Water solubility prediction: For the peptides predicted to be potentially biologically active (PeptideRanker>0.5), water solubility prediction was performed in Proteomics tools under the INNOVAGEN website to screen for peptides with “Good” water solubility;

[0066] Toxicity prediction: The peptides with good water solubility obtained by screening were used for peptide toxicity prediction under the "BatchSubmission" module of the Toixinpred website, and "Non-Toxin" peptides were selected;

[0067] Allergy prediction: The non-toxic peptides screened were used for allergy prediction in the "AllerTOPServerPage" and the "NON-ALLERGEN" peptides were selected;

[0068] (3) Molecular docking screening of peptides that dually inhibit DPP-Ⅳ and ACE enzyme activity

[0069] 48 peptides were screened from the above six dimensions, of which pentapeptides, hexapeptides and heptapeptides were the majority. Molecular docking was further used to screen peptides that could bind well to both DPP-IV and ACE enzymes. The specific experimental steps were as follows:

[0070] Preprocessing of macromolecular receptors: Download the X-ray diffraction protein three-dimensional structures of the human DPP-IV crystal complex 2ONC (https: / / www.rcsb.org / structure / 2ONC) and the human ACE crystal complex 1O8A (https: / / www.rcsb.org / structure / 1O8A) from the PDB database (http: / / www.rcsb.org), and use Autodocktools 1.5.6 to process the protein structure: remove water, delete the ligand, add hydrogen, calculate the charge, merge non-polar hydrogen, and further optimize the protein three-dimensional structure. After processing, export it to PDB format.

[0071] Small molecule ligand preprocessing: Import the peptide to be docked on the website (https: / / cloud.yinfotek.com / ), process the small molecule structure in Autodocktools1.5.6, add full hydrogen, automatically distribute charges, detect torsion bonds, and export to PDB format after processing.

[0072] Docking and analysis: The hydrophobic cavity located in the connection area between the α / β-hydrolysis domain and the β-helix region of the DPP-Ⅳ enzyme in the 2ONC crystal structure was set as the main active site, and the center coordinates of the active pocket site were set to (58.12, 60.43, 62.77). Similarly, the position of Zn2+ in the 1O8A crystal structure was set as the active site, and the center coordinates of the active pocket site were set to (36.99, 41.25, 43.45). The number of grid points in each XYZ direction was set to 50×50×50, the grid spacing was 0.375Å, the number of dockings was set to 100, and the other parameters were set to default values. Peptides with higher binding energies with 2ONC and 1O8A crystals than those with positive controls sitagliptin (DPP-Ⅳ inhibitor) and captopril (ACE inhibitor) were selected, and the interaction pattern between the receptor and the ligand was analyzed and visualized using Pymol2.3.0.

[0073] From the molecular docking calculation of binding energy, three peptides that can bind well to both DPP-IV and ACE enzyme were screened out, namely LDHGFP (LP-6), EGCPLLKGPGP and WGLPAKPE. Their docking binding energies with DPP-IV and ACE enzyme are -8.1 and -10.0 kcal / mol, -9.1 and -9.0 kcal / mol, and -10.3 and -7.7 kcal / mol, respectively.

[0074] The specific visualization docking results are as follows: Figure 5 As shown, hydrogen bonds, π-cation interactions, π-π stacking, salt bridges, etc. were formed between the polypeptide LDHGFP and the amino acid residues Arg61, Thr156, Trp157 and Arg61 at the action site of DPP-Ⅳ; hydrogen bonds, π-π interactions, etc. were formed between the polypeptide LDHGFP and the residues Lys449, Thr302, Glu376, Asp153 and Ser284 at the action site of ACE enzyme, thereby leading to a decrease in the activity of DPP-Ⅳ and ACE enzymes.

[0075] Example 4 Verification of the inhibitory activity of DPP-Ⅳ and ACE dual inhibitory peptides

[0076] The peptides LDHGFP, EGCPLLKGPGP and WGLPAKPE obtained by screening in Example 3 were synthesized by Fmoc solid phase synthesis method, and were respectively prepared into solutions with a concentration of 1.0 mg / mL using corresponding buffers. The inhibition rates of the samples on DPP-IV and ACE enzymes were determined, and the detection method was referred to Example 2.

[0077] The experimental results are as follows Figure 6As shown in the figure, among the sequences screened, the inhibition rates of DPP-Ⅳ and ACE of peptide LDHGFP were 74.3±2.23% and 75.18±2.26%, respectively; the inhibition rates of DPP-Ⅳ and ACE of EGCPLLKGPGP were only 22.56±1.13% and 49.34±1.48%, respectively; although the docking binding energy of EGCPLLKGPGP with the crystal structure of DPP-Ⅳ and ACE was high, its inhibitory activity was poor, with an inhibition rate of 94.22±2.83% for ACE enzyme and only 8.11±0.41% for DPP-Ⅳ enzyme; the inhibition rate of peptide WGLPAKPE for DPP-Ⅳ enzyme was 44.61±2.23%, and the inhibition rate for ACE enzyme was only 4.19±0.13%, which did not have good dual inhibitory activity. The results show that even peptides with high binding energy in computer simulation experiments may not necessarily achieve the corresponding effect in the actual inhibition process.

[0078] Example 5 Half Inhibitory Concentration IC50 and Cytotoxicity Test of Peptide LP-6

[0079] (1) Referring to the method of Example 4, the inhibition rate of LP-6 (LDHGFP) on DPP-IV and ACE enzymes at concentrations of 0.0625, 0.125, 0.25, 0.5, and 1.0 mg / mL was detected, and the IC50 was obtained by fitting.

[0080] The results are as follows Figure 7 As shown, the IC50 values ​​of peptide LP-6 against DPP-Ⅳ and ACE are 0.3221mM and 0.2521mM, respectively, proving that the peptide can achieve dual inhibitory effects at lower concentrations.

[0081] (2) Caco-2 cells were used for cell proliferation toxicity assay. Caco 2 cells were cultured at 6×10 3 / well were added to a 96-well plate and cultured overnight, and then LP-6 (0.5-2 mg / mL) was added and cultured for 24 h. A blank control and a 20% DMSO solvent group with the same amount of LP-6 were set up, and the cell proliferation toxicity test was performed using CCK 8 reagent.

[0082] like Figure 8 As shown, the relative cell viabilities when the addition amounts of LP-6 were 0.5, 1.0, and 2.0 mg / mL were 96.73±3.86%, 103.60±3.11%, and 102.57±5.13%, respectively, indicating that there was no significant toxic effect on Caco-2 cells.

[0083] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A DPP-IV and ACE dual inhibitory peptide derived from Lentinus edodes stem protein, characterized in that The following peptides: LP-6, whose amino acid sequence is LDHGFP.

2. The DPP-IV and ACE dual inhibitory peptide derived from Lentinus edodes stipe protein according to claim 1, characterized in that: The shiitake mushroom stalk protein-derived DPP-IV and ACE dual inhibitory peptide is prepared by chemical synthesis or biological enzymatic hydrolysis.

3. Use of the Lentinus edodes stipe protein-derived DPP-IV and ACE dual inhibitory peptide according to claim 1 in the preparation of drugs for lowering blood sugar and / or treating hypertension.

4. Use of the Lentinus edodes stipe protein-derived DPP-IV and ACE dual inhibitory peptide according to claim 1 in the preparation of a drug capable of simultaneously lowering blood sugar and treating hypertension.

5. Use of the Lentinus edodes stipe protein-derived DPP-IV and ACE dual inhibitory peptide according to claim 1 in the preparation of a health product with auxiliary blood sugar lowering function and / or auxiliary blood pressure lowering function.

6. Use of the Lentinus edodes stipe protein-derived DPP-IV and ACE dual inhibitory peptide according to claim 1 in the preparation of a health product having both the auxiliary blood sugar lowering function and the auxiliary blood pressure lowering function.

Citation Information

Patent Citations

  • Nonapeptide with angiotensin-converting enzyme (ACE) and dipeptidyl peptidase-IV (DPP-IV) dual inhibitory activity and application thereof

    CN106554387A

  • Broccoli protein derived ACE and DPP-IV inhibitory peptide, and preparation method and applications thereof

    CN110790818A

  • Ace inhibitory peptide composition derived from ginkgo protein and preparation method and application thereof

    US20220257705A1

  • Polypeptide having inhibitory effect against infection by novel coronavirus hcov-EMC 2012 and application of the polypeptide

    WO2014154134A1